Risk of anemia attributable to everolimus in patients with cancer: A meta-analysis of randomized controlled trials

Anticancer Research

Volumn 35, Issue 4, 2015, Pages 2333-2340

  Shameem, Raji ^a   Hamid, Muhammad Saad ^b   Wu, Shenhong ^c,d  

^a FOX CHASE CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Everolimus; mTOR inhibitor; mTOR inhibitor associated anemia

Indexed keywords

EVEROLIMUS; EXEMESTANE; HEMOGLOBIN; LETROZOLE; NAVELBINE; PLACEBO; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANEMIA; ANGIOMYOLIPOMA; ARTICLE; ATTRIBUTABLE RISK; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; METASTATIC COLORECTAL CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STOMACH CANCER; TUBEROUS SCLEROSIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MEDLINE; NEOPLASMS; PATHOLOGY;

ANEMIA; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84928392125     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Khokhar, NZ, Altman JK and Platanias LC: Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 23: 578-586, 2011.
2. Gomez-Pinillos A and Ferrari AC: mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 26: 483-505, 2012.
3. Yuan R, Kay A, Berg WJ and Lebwohl D: Targeting tumori genesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2: 45, 2009.
4. Amato R and Stepankiw M: Evaluation of everolimus in renal cell cancer. Expert Opin Pharmacother 14: 1229-1240, 2013.
5. National Cancer Institute. CTC v3.0 and Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2006. Available at http://ctep.cancer. gov/protocolDevelopment/electronic-applications/doc/ctcaev3.pdf. Accessed October, 2014.
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of reports of randomized clinical trials. Control Clin Trials 17: 1-12, 1996.
7. Andre F, O'Regan R, Ozguroglu M, Toi M, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T and Gianni L: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomized, double-blind, placebo-controlled phase III trial. Lancet Oncol 15: 580-591, 2014.
8. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoise S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C and Pujade-Lauraine E: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO Study. J Clin Oncol 30: 2718-2724, 2012.
9. Baselga J, Semiglazov V, Van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W and Rugo HS: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2630-2637, 2009.
10. Baselga J, Campone M, Piccalt M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D and Hortobagyi GN: Everolimus in postmenopausal homone-receptor-positive advanced breast cancer. N Eng J Med 366: 520-529, 2012.
11. Bissler J, Kingswood J, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D and Budde K: Everolimus for angiomyolipoma associated with tuberlous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomized, double-blind, placebo controlled trial. Lancet 381: 817-824, 2013.
12. Motzer R, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N Kay A and Ravaud A; RECORD - 1 Study Group: Phase III trial of everolimus for metastatic renal cell carcinoma. Cancer 116: 4256-4265, 2010.
13. Ohtsu A, Ajani J, Bai YX, Banf YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D and Van Cutsem E: Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31: 3935-3943, 2013.
14. Pavel M, Hainsworth J, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E and Yao JC; RADIANT-2 Study Group: Everolimus pus octreotide long acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase III study. Lancet 378: 2005-2012, 2011.
15. Yao J, Shah M, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D and Öberg K: Everolimus for advanced pancreatic neuroendocrine Tumors. N End J Med 364: 514-523, 2011.
16. Caro JJ, Salas M, Ward A and Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91: 2214-2221, 2001.
17. Barni S, Cabiddu M, Guarneri P, Lonati V and Petrelli F: The risk for anemia with targeted therapies for solid tumors. Oncologist 17: 715-724, 2012.
18. Harper P and Littlewood T: Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 69: 2-7, 2005.
19. Lambea J, Hinojo C, Lainez N, Lázaro M, León L, Rodriguez A, Soto de Prado D and Esteban E: Quality of life and supportive care for patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 31: S33-39, 2012.
20. Lappin, T: The changing face of anemia treatment. Oncologist 16: 1-2, 2011.
21. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Scheider M and Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Oncology 70: 34-48, 2006.
22. Kim KH, Yoon SH, Lee HJ, Kim HS, Shin SJ, Ahn JB and Rha SY: Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 72: 853-860, 2013.
23. Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Carteni G, Appetecchia M, Berruti A, Colao A, Falconi M and Delle Fave G: Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 19: 966-974, 2014.
24. van den Eertwegh AJ, Karakiewicz P, Bavbek S, Rha SY, Bracarda S, Bahl A, Ou YC, Kim D, Panneerselvam A, Anak O and Grünwald V: Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. Urology 81: 143-149, 2013.
25. Funakoshi T, Latif A and Galsky MD: Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis. Crit Rev Oncol Hematol 88: 30-41, 2013.
26. Xu J and Tian D: Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. Curr Med Res Opin 30: 67-74, 2014.
27. Mondesire WH, Kian W, Zhang H, Ensor J, Hung MC, Mills GB and Meric-Bernstam F: Targeting Mammalian target of rapamycin synergistically enhances chemotherapy-induced cyto toxicity in breast cancer cells. Clin Cancer Res 10: 7031-7042, 2004.
28. Zhu Y, Zhang X, Lui Y, Zhang S, Liu J, Ma Y and Zhang J: Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumour Biol 33: 1349-1362, 2012.
29. Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T and Gianni L: Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-over expressing metastatic breast cancer. Breast Cancer Res Treat 125: 447-455, 2011.
30. Spivak JL, Gascón P and Ludwig H: Anemia management in oncology and hematology. Oncologist 14: 43-56, 2009.
31. Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers M, Shasha D and Van Belle S: Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 68: 3-11, 2005.
32. Ludwig H and Fritz E. Anemia in Cancer Patients. Semin Oncology 29: 2-8, 1993.
33. Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M and Barrientos A: Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal trans plant patients. Transplant Proc 39: 2242-2244, 2007.
34. Quesniaux VF, Wehrli S, Steiner C, Joergensen J, Schuurman HJ, Herman P, Schreier MH and Schuler W: The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 84: 1543-1552, 1994.
35. Quesniaux VF, Wehrli S, Wioland C, Schuler W and Schreier MH: Effects of rapamycin on hematopoiesis. Transplant Proc 26: 3135-3140, 1994.
36. Chen A, Chen L, Al-Qaisi A, Romond E, Awasthi M, Kadamyan-Melkumyan V and Massarweh S: Everolimus-induced hematologic changes in patients with metastatic breast cancer. Clin Breast Cancer; accepted August 2014, in press, 2014.
37. Méndez-Vidal MJ, Martínez Ortega E, Montesa Pino A, Pérez Valderrama B and Viciana R: Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 31: 19-27, 2012.
38. Peterson ME: Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 21: 2341-2349, 2013.
39. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH and Somerfield MR: American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. JOP 116: 4045-4059, 2010.
40. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B and Goodnough LT: Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 28: 801-831, 2006.
41. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A and Bohlius J: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12: CD0034007, 2012.
42. Rodgers GM, Becker PS, Blinder M, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G and Weir AB 3rd: Cancer-and chemotherapy-induced anemia. J Natl Compr Canc Netw 10: 628-653, 2012.
43. Afinitor® (everolimus) tablets [summary of product information], Stein, Swizterland: Novartis Pharma Stein AG; 2014. http://www.pharma.us.novartic.com/product/pi/pdf/ affinitor.pdf Accessed October, 2014.
44. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O' Toole T, Lustgarten S, Moore L and Motzer RJ; Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Eng J Med 356: 2271-2281, 2007.
45. Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF and Blay JY: Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 31: 2485-2492, 2013.
46. placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J ClinOncol 31: 2485-2492, 2013.